| Literature DB >> 35456227 |
Jong Woo Lee1, Jae Hyun Kwon1, Jung Woo Lee1.
Abstract
Laparoscopic surgery has been traditionally contraindicated for gallbladder cancer, but there have been few reports demonstrating the oncologic outcomes of this treatment. This study aimed to compare the technical feasibility and the long-term outcomes after laparoscopic versus open extended cholecystectomy for gallbladder cancer. Between January 2011 and December 2018, 44 patients with gallbladder cancer who underwent extended cholecystectomy were included in this study, with 20 patients in the laparoscopic group and 24 patients in the open group. Perioperative outcomes, overall survival (OS), and recurrence-free survival (RFS) were retrospectively analyzed. There were no significant differences (p > 0.05) between the two groups in terms of perioperative outcomes, including blood loss, postoperative complications, R0 resection, and the number of lymph nodes retrieved. Patients in the laparoscopic group showed similar OS compared to the open group (5 year tumor-specific OS rate: 84.7% vs. 62.5%; p = 0.125). On subgroup analysis of patients with stage T2 and N0 disease, the laparoscopic group showed better OS (T2: 90.9% vs. 75.0%, p = 0.256; N0: 100.0% vs. 76.5%, p = 0.028). There was no difference in terms of RFS (3 year RFS: 74.4% vs. 64%; p = 0.571) and locoregional recurrence (10.0% vs. 16.9%, p = 0.895) between the two groups. There was no port-site recurrence in the laparoscopic group. This study suggests that laparoscopic extended cholecystectomy might be not inferior to open surgery in terms of oncologic safety or early and long-term outcomes in patients with early gallbladder cancer.Entities:
Keywords: extended cholecystectomy; gallbladder cancer; laparoscopic resection; open surgery
Year: 2022 PMID: 35456227 PMCID: PMC9027168 DOI: 10.3390/jcm11082132
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Baseline characteristics of patients with gallbladder cancer who underwent laparoscopic and open extended cholecystectomy.
| Laparoscopic Group ( | Open Group ( | ||
|---|---|---|---|
| Age, years | 71.85 ± 9.11 | 68.08 ± 10.64 | 0.219 |
| BMI, kg/m2 | 24.88 ± 2.98 | 24.39 ± 2.70 | 0.568 |
| Sex, | 0.153 | ||
| Male | 5 (25.0) | 11 (45.8) | |
| Female | 15 (75.0) | 13 (54.2) | |
| Diabetes mellitus, | 7 (35.0) | 10 (41.7) | 0.651 |
| Hypertension, | 10 (50.0) | 14 (58.3) | 0.580 |
| Hepatitis, | 0 (0.0) | 2 (8.3) | 0.493 |
| Liver cirrhosis, | 0 (0.0) | 1 (4.2) | 1.000 |
| Preoperative bilirubin, mg/dL | 0.58 ± 0.26 | 0.83 ± 0.68 | 0.119 |
| Preoperative albumin, g/dL | 3.97 ± 0.46 | 3.90 ± 0.42 | 0.557 |
| Preoperative CA19-9, U/mL | 10.65 ± 7.51 | 24.56 ± 29.54 | 0.097 |
| Postoperative CA19-9, U/mL | 10.64 ± 7.40 | 20.68 ± 19.99 | 0.040 * |
| Incidental GBC, | 7 (35.0) | 7 (29.2) | 0.679 |
| Open conversion, | – | 2 (8.3) | – |
| Adjuvant chemotherapy, | 6 (30.0) | 10 (41.7) | 0.423 |
| Liver resection, | 0.034 | ||
| No | 1 (5.0) | 1 (4.2) | |
| Wedge | 4 (20.0) | 13 (54.2) | |
| S4b/5 | 15 (75.0) | 10 (41.7) | |
| Extrahepatic common bile duct resection, | 1 (5.0) | 3 (12.5) | 0.614 |
| Overall survival, months | 51.28 ± 25.81 | 51.65 ± 34.29 | 0.969 |
| Recurrence-free survival, months | 48.9 ± 27.76 | 46.46 ± 35.54 | 0.804 |
* Statistical significant p-value (<0.05), BMI, body mass index; GBC, gallbladder cancer; CA19-9, carbohydrate antigen 19-9.
Comparison of operative outcomes in laparoscopic and open group.
| Laparoscopic Group ( | Open Group ( | ||
|---|---|---|---|
| Operative time, min | 186.60 ± 88.14 | 231.67 ± 82.97 | 0.088 |
| Estimated blood loss, mL | 320.00 ± 451.72 | 593.75 ± 912.04 | 0.205 |
| Transfusion, | 6 (30.0) | 12 (50.0) | 0.179 |
| R0 resection, | 19 (95.0) | 23 (95.8) | 1.000 |
| Postoperative complications, | 2 (10.0) | 5 (20.8) | 0.428 |
| Bile leakage | 1 (5.0) | 0 (0.0) | 0.455 |
| Abdominal fluid collection | 1 (5.0) | 4 (16.7) | 0.673 |
| Pulmonary complication | 0 (0.0) | 1 (4.2) | 1.000 |
| Postoperative hospital stay, days | 10.95 ± 4.82 | 12.80 ± 4.87 | 0.216 |
| 90-day mortality, | 0 (0.0) | 1 (4.2) | 1.000 |
Comparison of histopathologic outcomes in laparoscopic and open group.
| Laparoscopic Group ( | Open Group ( | ||
|---|---|---|---|
| Tumor size, cm | 3.21 ± 1.90 | 3.64 ± 2.31 | 0.223 |
| Perineural invasion, | 3 (17.6) | 2 (15.4) | 1.000 |
| Lymphovascular invasion, | 3 (16.7) | 2 (8.7) | 0.638 |
| Grade, | 0.549 | ||
| Well/moderate | 15 (75.0) | 14 (58.3) | |
| Poor/undifferentiated | 3 (15.0) | 5 (20.8) | |
| Unknown | 2 (10.0) | 5 (20.8) | |
| pT stage, | 0.906 | ||
| T1 | 4 (20.0) | 5 (20.8) | |
| T2 | 12 (60.0) | 16 (66.7) | |
| T3 | 4 (20.0) | 3 (12.5) | |
| pN stage | 0.457 | ||
| N0 | 14 (70.0) | 17 (70.8) | |
| N1 | 2 (10.0) | 5 (20.8) | |
| Nx | 4 (20.0) | 2 (8.3) | |
| Pathologic stage ( | 0.780 | ||
| I | 4 (20.0) | 4 (16.7) | |
| II | 11 (55.0) | 12 (50.0) | |
| IIIA | 2 (10.0) | 2 (8.3) | |
| IIIB | 2 (10.0) | 4 (16.7) | |
| IVA | 1 (5.0) | 2 (8.3) | |
| Hepatic invasion, | 3 (15.0) | 3 (12.5) | 1.000 |
| Lymph node metastasis, | 2 (10.0) | 5 (20.8) | 0.328 |
| Number of retrieved lymph nodes | 5.75 ± 3.54 | 6.75 ± 4.17 | 0.402 |
Details of disease recurrence and treatment.
| Laparoscopic Group ( | Open Group ( | ||
|---|---|---|---|
| Recurrence, | 0.895 | ||
| None | 15 (75.0) | 16 (66.7) | |
| Locoregional | 2 (10.0) | 4 (16.7) | |
| Distant | 3 (15.0) | 4 (16.7) | |
| Recurrence site, | |||
| Port-site or incisional site | 0 (0.0) | 0 (0.0) | – |
| Regional lymph nodes | 2 (10.0) | 3 (12.5) | 1.000 |
| Liver | 2 (10.0) | 2 (8.3) | 1.000 |
| Liver cut surface | 0 (0.0) | 2 (8.3) | 0.493 |
| Peritoneum | 2 (10.0) | 2 (8.3) | 1.000 |
| Chemotherapy after recurrence ( | 2/5 (40) | 8/8 (100) | 0.035 * |
* Statistical significant p-value (<0.05).
Figure 1Overall survival between the laparoscopic and open groups in the overall cohort (n = 44) (a), T2 patients (n = 28) (b), and N0 patients (n = 31) (c).
Figure 2Tumor-specific overall survival between the laparoscopic and open groups in the overall cohort (n = 44) (a), T2 patients (n = 28) (b), and N0 patients (n = 31) (c).
Figure 3Recurrence-free survival between the laparoscopic and open groups in the overall cohort (n = 44) (a), T2 patients (n = 28) (b), and N0 patients (n = 31) (c).